You are here
Unmet Needs and Rationale for Combination Therapies for Primary Care Physicians
for Primary Care Physicians
In this course, you will learn about the rationale for adding a glucagon-like peptide-1 (GLP-1) receptor agonist to basal insulin therapy. The complementary effects of basal insulin–GLP-1 receptor agonist combination therapy will be discussed in terms of glycaemic control, change in body weight, and risk of hypoglycaemia. After completing this course, you will be able to identify patients for whom basal insulin–GLP-1 receptor agonist combination therapy may be a viable option, and also learn some practical tips on how to best manage these patients. Sign up to the E-Alert to be updated on all new publications.
Developed by Elsevier B.V., supported by an unrestricted educational grant from Novo Nordisk